<DOC>
	<DOCNO>NCT01993420</DOCNO>
	<brief_summary>The purpose study determine whether DRM02 safe effective treatment atopic dermatitis apply twice daily 6 week .</brief_summary>
	<brief_title>A Safety Efficacy DRM02 Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>This double-blind , randomize , within-subject control , study enrol 20 subject atopic dermatitis design assess safety , tolerability , preliminary efficacy DRM02 . Safety assess study , adverse event , local skin response , urinalysis , serum chemistry hematology laboratory testing , physical examination vital sign . Preliminary efficacy assess Physician 's Lesion Assessment ( PLA ) Eczema Area Severity Index ( EASI ) two lesion identify baseline visit .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female 18 70 year age . Clinical diagnosis stable atopic dermatitis ( AD ) two lesion similar size identical score least 5 9 sum individual component Eczema Area Severity Index ( EASI ) Target Lesion scale . Male nonpregnant , nonlactating female . Signed informed consent . Subjects unstable atopic dermatitis ( AD ) . Significant infection target lesion site . Prior concomitant use systemic therapy AD within past 4 week . Prior concomitant use topical treatment AD , within 10 cm target lesion within past 4 week . Prior concomitant use oral retinoids AD within last 6 month . Use biologics AD within past 3 month , 5 halflives ( whichever longer ) . Subjects poor skin condition within 5 cm target lesion . Subjects current drug alcohol abuser ; history immunodeficiency disease ; poor medical risk systemic disease active uncontrolled infection . Subjects unstable medical condition medical condition adequately control standard medical therapy . Subjects actively participate experimental therapy study receive experimental therapy within 30 day . Subjects clinically significant laboratory value screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>